New York
Alzheimer's disease clinical trials in New York
44 Alzheimer's disease studies are recruiting participants at sites in 17 cities across New York as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every New York city with a recruiting study
New York (22), Albany (5), Syracuse (5), Rochester (4), Woodmere (4), Buffalo (3), Laurelton (3), New Windsor (3), Staten Island (3), Manhasset (2), Amherst (1), Brooklyn (1), Orangeburg (1), Queens (1), Rosedale (1), Valley Stream (1), White Plains (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Recently updated studies in New York
Basic details from each study's public record (the 12 most recently updated of 44). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Phase 3
- Ages 50 to 90
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Laurelton · New York · Rochester
- Registry record
- NCT07177352 · updated
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
- Phase 2
- Ages 50 to 90
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Laurelton
- Registry record
- NCT07781657 · updated
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Recruiting in
- Woodmere
- Registry record
- NCT05980949 · updated
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- MapLight Therapeutics
- Recruiting in
- New York
- Registry record
- NCT06887192 · updated
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Woodmere
- Registry record
- NCT07011732 · updated
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
- Phase 2/3
- Ages 55 to 90
- All sexes
- Sponsor
- Exciva GmbH
- Recruiting in
- Brooklyn · New York
- Registry record
- NCT07284472 · updated
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Phase 3
- Ages 55 to 80
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Laurelton
- Registry record
- NCT07717411 · updated
ACP-204 in Adults With Alzheimer's Disease Psychosis
- Phase 2/3
- Ages 55 to 95
- All sexes
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Recruiting in
- Syracuse
- Registry record
- NCT06159673 · updated
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- Staten Island · Valley Stream
- Registry record
- NCT07011745 · updated
Triage Survey for Neurology Research Eligibility
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- Adams Clinical
- Recruiting in
- New York
- Registry record
- NCT06104852 · updated
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Recruiting in
- New Windsor · Syracuse · Woodmere
- Registry record
- NCT06585787 · updated
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Phase 3
- Ages 60 to 85
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Recruiting in
- New York · Syracuse
- Registry record
- NCT06976216 · updated
Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in New York on ClinicalTrials.gov.
Ask about studies in New York
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections